Metabolic Disorder Therapeutics Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2021-2030

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Metabolic Disorder Therapeutics Market, By Disease

7.1.  Metabolic Disorder Therapeutics Market, By Disease, 2021-2028

7.1.1.    Lysosomal Storage Diseases

7.1.1.1.        Market Revenue and Forecast (2016-2028)

7.1.2.    Diabetes

7.1.2.1.        Market Revenue and Forecast (2016-2028)

7.1.3.    Obesity

7.1.3.1.        Market Revenue and Forecast (2016-2028)

7.1.4.    Inherited Metabolic Disorders

7.1.4.1.        Market Revenue and Forecast (2016-2028)

7.1.5.    Hypercholesterolemia

7.1.5.1.        Market Revenue and Forecast (2016-2028)

Chapter 8.  Global Metabolic Disorder Therapeutics Market, By Therapy Type

8.1.  Metabolic Disorder Therapeutics Market, By Therapy Type, 2021-2028

8.1.1.    Enzyme Replacement Therapy

8.1.1.1.        Market Revenue and Forecast (2016-2028)

8.1.2.    Cellular Transplantation

8.1.2.1.        Market Revenue and Forecast (2016-2028)

8.1.3.    Small Molecule Based Therapy

8.1.3.1.        Market Revenue and Forecast (2016-2028)

8.1.4.    Substrate Reduction Therapy

8.1.4.1.        Market Revenue and Forecast (2016-2028)

8.1.5.    Gene Therapy

8.1.5.1.        Market Revenue and Forecast (2016-2028)

8.1.6.    Drug Therapy

8.1.6.1.        Market Revenue and Forecast (2016-2028)

Chapter 9.  Global Metabolic Disorder Therapeutics Market, By Route of Administration

9.1.  Metabolic Disorder Therapeutics Market, By Route of Administration, 2021-2028

9.1.1.    Oral

9.1.1.1.        Market Revenue and Forecast (2016-2028)

9.1.2.    Parenteral

9.1.2.1.        Market Revenue and Forecast (2016-2028)

Chapter 10.      Global Metabolic Disorder Therapeutics Market, Regional Estimates and Trend Forecast

10.1.        North America

10.1.1.  Market Revenue and Forecast, By Disease (2016-2028)

10.1.2.  Market Revenue and Forecast, By Therapy Type (2016-2028)

10.1.3.  Market Revenue and Forecast, By Route of Administration (2016-2028)

10.1.4.  U.S.

10.1.4.1.      Market Revenue and Forecast, By Disease (2016-2028)

10.1.4.2.      Market Revenue and Forecast, By Therapy Type (2016-2028)

10.1.4.3.      Market Revenue and Forecast, By Route of Administration (2016-2028)

10.1.5.  Rest of North America

10.1.5.1.      Market Revenue and Forecast, By Disease (2016-2028)

10.1.5.2.      Market Revenue and Forecast, By Therapy Type (2016-2028)

10.1.5.3.      Market Revenue and Forecast, By Route of Administration (2016-2028)

10.2.        Europe

10.2.1.  Market Revenue and Forecast, By Disease (2016-2028)

10.2.2.  Market Revenue and Forecast, By Therapy Type (2016-2028)

10.2.3.  Market Revenue and Forecast, By Route of Administration (2016-2028)

10.2.4.  UK

10.2.4.1.      Market Revenue and Forecast, By Disease (2016-2028)

10.2.4.2.      Market Revenue and Forecast, By Therapy Type (2016-2028)

10.2.4.3.      Market Revenue and Forecast, By Route of Administration (2016-2028)

10.2.5.  Germany

10.2.5.1.      Market Revenue and Forecast, By Disease (2016-2028)

10.2.5.2.      Market Revenue and Forecast, By Therapy Type (2016-2028)

10.2.5.3.      Market Revenue and Forecast, By Route of Administration (2016-2028)

10.2.6.  France

10.2.6.1.      Market Revenue and Forecast, By Disease (2016-2028)

10.2.6.2.      Market Revenue and Forecast, By Therapy Type (2016-2028)

10.2.6.3.      Market Revenue and Forecast, By Route of Administration (2016-2028)

10.2.7.  Rest of Europe

10.2.7.1.      Market Revenue and Forecast, By Disease (2016-2028)

10.2.7.2.      Market Revenue and Forecast, By Therapy Type (2016-2028)

10.2.7.3.      Market Revenue and Forecast, By Route of Administration (2016-2028)

10.3.        APAC

10.3.1.  Market Revenue and Forecast, By Disease (2016-2028)

10.3.2.  Market Revenue and Forecast, By Therapy Type (2016-2028)

10.3.3.  Market Revenue and Forecast, By Route of Administration (2016-2028)

10.3.4.  India

10.3.4.1.      Market Revenue and Forecast, By Disease (2016-2028)

10.3.4.2.      Market Revenue and Forecast, By Therapy Type (2016-2028)

10.3.4.3.      Market Revenue and Forecast, By Route of Administration (2016-2028)

10.3.5.  China

10.3.5.1.      Market Revenue and Forecast, By Disease (2016-2028)

10.3.5.2.      Market Revenue and Forecast, By Therapy Type (2016-2028)

10.3.5.3.      Market Revenue and Forecast, By Route of Administration (2016-2028)

10.3.6.  Japan

10.3.6.1.      Market Revenue and Forecast, By Disease (2016-2028)

10.3.6.2.      Market Revenue and Forecast, By Therapy Type (2016-2028)

10.3.6.3.      Market Revenue and Forecast, By Route of Administration (2016-2028)

10.3.7.  Rest of APAC

10.3.7.1.      Market Revenue and Forecast, By Disease (2016-2028)

10.3.7.2.      Market Revenue and Forecast, By Therapy Type (2016-2028)

10.3.7.3.      Market Revenue and Forecast, By Route of Administration (2016-2028)

10.4.        MEA

10.4.1.  Market Revenue and Forecast, By Disease (2016-2028)

10.4.2.  Market Revenue and Forecast, By Therapy Type (2016-2028)

10.4.3.  Market Revenue and Forecast, By Route of Administration (2016-2028)

10.4.4.  GCC

10.4.4.1.      Market Revenue and Forecast, By Disease (2016-2028)

10.4.4.2.      Market Revenue and Forecast, By Therapy Type (2016-2028)

10.4.4.3.      Market Revenue and Forecast, By Route of Administration (2016-2028)

10.4.5.  North Africa

10.4.5.1.      Market Revenue and Forecast, By Disease (2016-2028)

10.4.5.2.      Market Revenue and Forecast, By Therapy Type (2016-2028)

10.4.5.3.      Market Revenue and Forecast, By Route of Administration (2016-2028)

10.4.6.  South Africa

10.4.6.1.      Market Revenue and Forecast, By Disease (2016-2028)

10.4.6.2.      Market Revenue and Forecast, By Therapy Type (2016-2028)

10.4.6.3.      Market Revenue and Forecast, By Route of Administration (2016-2028)

10.4.7.  Rest of MEA

10.4.7.1.      Market Revenue and Forecast, By Disease (2016-2028)

10.4.7.2.      Market Revenue and Forecast, By Therapy Type (2016-2028)

10.4.7.3.      Market Revenue and Forecast, By Route of Administration (2016-2028)

10.5.        Latin America

10.5.1.  Market Revenue and Forecast, By Disease (2016-2028)

10.5.2.  Market Revenue and Forecast, By Therapy Type (2016-2028)

10.5.3.  Market Revenue and Forecast, By Route of Administration (2016-2028)

10.5.4.  Brazil

10.5.4.1.      Market Revenue and Forecast, By Disease (2016-2028)

10.5.4.2.      Market Revenue and Forecast, By Therapy Type (2016-2028)

10.5.4.3.      Market Revenue and Forecast, By Route of Administration (2016-2028)

10.5.5.  Rest of LATAM

10.5.5.1.      Market Revenue and Forecast, By Disease (2016-2028)

10.5.5.2.      Market Revenue and Forecast, By Therapy Type (2016-2028)

10.5.5.3.      Market Revenue and Forecast, By Route of Administration (2016-2028)

Chapter 11.  Company Profiles

11.1.              Novo Nordisk A/S

11.1.1.  Company Overview

11.1.2.  Product Offerings

11.1.3.  Financial Performance

11.1.4.  Recent Initiatives

11.2.              Sanofi S.A.

11.2.1.  Company Overview

11.2.2.  Product Offerings

11.2.3.  Financial Performance

11.2.4.  Recent Initiatives

11.3.              Boehringer Ingelheim GmbH

11.3.1.  Company Overview

11.3.2.  Product Offerings

11.3.3.  Financial Performance

11.3.4.  Recent Initiatives

11.4.              Eli Lilly and Company

11.4.1.  Company Overview

11.4.2.  Product Offerings

11.4.3.  Financial Performance

11.4.4.  Recent Initiatives

11.5.              Merck KgaA; Amgen, Inc.

11.5.1.  Company Overview

11.5.2.  Product Offerings

11.5.3.  Financial Performance

11.5.4.  Recent Initiatives

11.6.              AstraZeneca PLC

11.6.1.  Company Overview

11.6.2.  Product Offerings

11.6.3.  Financial Performance

11.6.4.  Recent Initiatives

11.7.              Actelion Pharmaceuticals Ltd.

11.7.1.  Company Overview

11.7.2.  Product Offerings

11.7.3.  Financial Performance

11.7.4.  Recent Initiatives

11.8.              Shire PLC

11.8.1.  Company Overview

11.8.2.  Product Offerings

11.8.3.  Financial Performance

11.8.4.  Recent Initiatives

11.9.              AbbVie, Inc.

11.9.1.  Company Overview

11.9.2.  Product Offerings

11.9.3.  Financial Performance

11.9.4.  Recent Initiatives

11.10.           Biocon Ltd.

11.10.1.               Company Overview

11.10.2.               Product Offerings

11.10.3.               Financial Performance

11.10.4.               Recent Initiatives

11.11.           BioMarin Pharmaceutical, Inc.

11.11.1.               Company Overview

11.11.2.               Product Offerings

11.11.3.               Financial Performance

11.11.4.               Recent Initiatives

11.12.           Bristol-Myers Squibb Company.

11.12.1.               Company Overview

11.12.2.               Product Offerings

11.12.3.               Financial Performance

11.12.4.               Recent Initiatives

11.13.           Cipla, Inc.

11.13.1.               Company Overview

11.13.2.               Product Offerings

11.13.3.               Financial Performance

11.13.4.               Recent Initiatives

11.14.           CymaBay Therapeutics, Inc

11.14.1.               Company Overview

11.14.2.               Product Offerings

11.14.3.               Financial Performance

11.14.4.               Recent Initiatives

Chapter 12.  Research Methodology

12.1.              Primary Research

12.2.              Secondary Research

12.3.              Assumptions

Chapter 13.  Appendix

13.1.              About Us

13.2.              Glossary of Terms

Report Details

  • Report Code:37295
  • Category:Healthcare
  • No. of Pages:250
  • Format:PDF/PPT/Excel
  • Published:February 2021
  • Historical Year:2021-2022
  • Base Year:2023
  • Estimated Year:2024-2033

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers